Participants eligible for inclusion in this study must fulfill all of the following criteria: 1. Completion of the written informed consent process (signed) with video recording of the verbal consent process, 2. Male or female age 18 to 64 years inclusive, in general good health equivalent to Army Medical Employment Classification J22 or above. Civilian personnel would need to be in good general health as advised by their General Practitioner (GP), 3. Not previously diagnosed with COVID-19, 4. Participant works in/in association with a healthcare facility or other high-risk environment characterised by high level of contact with persons thought likely to be infected with respiratory viruses, 5. Possess an internet enabled smart phone capable of receiving and responding to alerts, 6. Willing and able to comply with all scheduled visits, treatment plan, laboratory tests, and other study procedures, 7. Agrees not to self-medicate with chloroquine, hydroxychloroquine or other potential antivirals, and 8. Agree to stay in contact with the study site for the duration of the study and up to 2 weeks following the EOS visit (unless deployed), provide updated contact information as necessary.

Participants eligible for inclusion in this study must fulfill all of the following criteria: 1. Completion of the written informed consent process (signed) with video recording of the verbal consent process, 2. Male or female age 18 to 64 years inclusive, in general good health equivalent to Army Medical Employment Classification J22 or above. Civilian personnel would need to be in good general health as advised by their General Practitioner (GP), 3. Not previously diagnosed with COVID-19, 4. Participant works in/in association with a healthcare facility or other high-risk environment characterised by high level of contact with persons thought likely to be infected with respiratory viruses, 5. Possess an internet enabled smart phone capable of receiving and responding to alerts, 6. Willing and able to comply with all scheduled visits, treatment plan, laboratory tests, and other study procedures, 7. Agrees not to self-medicate with chloroquine, hydroxychloroquine or other potential antivirals, and 8. Agree to stay in contact with the study site for the duration of the study and up to 2 weeks following the EOS visit (unless deployed), provide updated contact information as necessary.